Press Release
CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270
IR@corcept.com
www.corcept.com
Corcept
Therapeutics to Present at C.E. Unterberg, Towbin
Emerging Growth Conference on July 11, 2006
MENLO PARK (July 7, 2006) -- Corcept Therapeutics Incorporated (Nasdaq: CORT) today announced that the company will present at the C.E. Unterberg, Towbin Emerging Growth Conference on Tuesday, July 11 at 8:00 a.m. (EDT) at the Mandarin Oriental Hotel in New York. The presentation will cover the company's clinical and corporate progress.
A live and subsequent archive of the Corcept presentation will be available on July 11, 2006 via webcast at: http://www.wsw.com/webcast/ceut4/cort/
The webcast will be
available for 2 weeks.
About Corcept Therapeutics
Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged
in the development of drugs for the treatment of severe psychiatric and
neurological diseases. Corcept's lead product, CORLUX®, is currently
in Phase III clinical trials for the treatment of the psychotic features
of psychotic major depression (PMD). The drug is administered orally to
PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist,
appears to mitigate the effects of the elevated and abnormal release patterns
of cortisol seen in PMD.
For additional information about the company, please visit www.corcept.com.